NMDA agonists and as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

John H. Krystal; D. Cyril D'Souza; Ismene L. Petrakis; Aysenil Belger; Robert M. Berman; Dennis S. Charney; Walid Abi-Saab; Steven Madonick

doi:10.3109/hrp.7.3.125

NMDA agonists and as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

John H. Krystal, D. Cyril D'Souza, Ismene L. Petrakis, Aysenil Belger, Robert M. Berman, Dennis S. Charney, Walid Abi-Saab, Steven Madonick

Research output: Contribution to journal › Review article › peer-review

243 Scopus citations

Abstract

Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors and agonists of the glycine-B coagonist site of these receptors have been important tools for characterizing the contributions of NMDA receptor pathophysiology to a large number of neuropsychiatric conditions and for treating these conditions. Among these disorders are Alzheimer's disease, chronic pain syndromes, epilepsy, schizophrenia, Parkinson's disease, Huntington's disease, addiction disorders, major depression, and anxiety disorders. This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists. It will also consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.

Original language	English
Pages (from-to)	125-143
Number of pages	19
Journal	Harvard Review of Psychiatry
Volume	7
Issue number	3
DOIs	https://doi.org/10.3109/hrp.7.3.125
State	Published - 1999
Externally published	Yes

Access to Document

10.3109/hrp.7.3.125

Cite this

@article{346befeec4f743059dc00fe38ade3194,

title = "NMDA agonists and as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders",

abstract = "Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors and agonists of the glycine-B coagonist site of these receptors have been important tools for characterizing the contributions of NMDA receptor pathophysiology to a large number of neuropsychiatric conditions and for treating these conditions. Among these disorders are Alzheimer's disease, chronic pain syndromes, epilepsy, schizophrenia, Parkinson's disease, Huntington's disease, addiction disorders, major depression, and anxiety disorders. This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists. It will also consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.",

author = "Krystal, {John H.} and D'Souza, {D. Cyril} and Petrakis, {Ismene L.} and Aysenil Belger and Berman, {Robert M.} and Charney, {Dennis S.} and Walid Abi-Saab and Steven Madonick",

year = "1999",

doi = "10.3109/hrp.7.3.125",

language = "English",

volume = "7",

pages = "125--143",

journal = "Harvard Review of Psychiatry",

issn = "1067-3229",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "3",

}

TY - JOUR

T1 - NMDA agonists and as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

AU - Krystal, John H.

AU - D'Souza, D. Cyril

AU - Petrakis, Ismene L.

AU - Belger, Aysenil

AU - Berman, Robert M.

AU - Charney, Dennis S.

AU - Abi-Saab, Walid

AU - Madonick, Steven

PY - 1999

Y1 - 1999

N2 - Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors and agonists of the glycine-B coagonist site of these receptors have been important tools for characterizing the contributions of NMDA receptor pathophysiology to a large number of neuropsychiatric conditions and for treating these conditions. Among these disorders are Alzheimer's disease, chronic pain syndromes, epilepsy, schizophrenia, Parkinson's disease, Huntington's disease, addiction disorders, major depression, and anxiety disorders. This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists. It will also consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.

AB - Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors and agonists of the glycine-B coagonist site of these receptors have been important tools for characterizing the contributions of NMDA receptor pathophysiology to a large number of neuropsychiatric conditions and for treating these conditions. Among these disorders are Alzheimer's disease, chronic pain syndromes, epilepsy, schizophrenia, Parkinson's disease, Huntington's disease, addiction disorders, major depression, and anxiety disorders. This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists. It will also consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.

UR - http://www.scopus.com/inward/record.url?scp=0033190699&partnerID=8YFLogxK

U2 - 10.3109/hrp.7.3.125

DO - 10.3109/hrp.7.3.125

M3 - Review article

C2 - 10483932

AN - SCOPUS:0033190699

SN - 1067-3229

VL - 7

SP - 125

EP - 143

JO - Harvard Review of Psychiatry

JF - Harvard Review of Psychiatry

IS - 3

ER -

NMDA agonists and as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

Abstract

Access to Document

Fingerprint

Cite this